Late relapse after CAR-T cell therapy for adult patients with hematologic malignancies: A definite evidence from systematic review and meta-analysis on individual data

Late relapse after CAR-T cell therapy for adult patients with hematologic malignancies: A definite evidence from systematic review and meta-analysis on individual data

Chimeric Antigen Receptor (CAR)-modified T lymphocytes represent one of the most innovative and promising approaches to treating hematologic malignancies. CAR-T cell therapy is currently being used for the treatment of relapsed/refractory (r/r) B-cell malignancies including Acute Lymphoblastic Leuke...

Full description

Bibliographic Details
Main Authors: Alessia Zinzi, Mario Gaio, Valerio Liguori, Cecilia Cagnotta, Donatella Paolino, Giuseppe Paolisso, Giuseppe Castaldo, Giovanni Francesco Nicoletti, Francesco Rossi, Annalisa Capuano, Concetta Rafaniello
Format: Article
Language:English
Published: Elsevier 2023-04-01
Series:Pharmacological Research
Subjects:
Chimeric antigen receptor
Relapse
Hematologic malignancies
Duration of response
Meta-analysis
Systematic review
Online Access:http://www.sciencedirect.com/science/article/pii/S1043661823000981

Internet

http://www.sciencedirect.com/science/article/pii/S1043661823000981

Similar Items